In the News
Memory Machine drives into town to promote brain health awareness on Oct. 6
Brain Matters Research and Neuropsychiatric Research Center of Southwest Florida take Alzheimer’s Disease clinical research on the road By Staff | Oct 4, 2023 Brain Matters Research and Neuropsychiatric Research Center of Southwest Florida will be driving clinical research into the community as they introduce the Memory Machine to Fort Myers. The new Memory Machine will allow […]
People with Down syndrome deserve access to Alzheimer’s treatment
People with Down syndrome helped scientists pave the way for Alzheimer’s drugs but are now left out of the treatment. By Hampus Hillerstrom and Jo Ann Simons The clinical trials for new Alzheimer’s disease treatment drugs — which researchers believe will slow the course of the disease over time — offer hope to thousands of […]
Sarasota researchers host memory screening for Alzheimer’s
By Sydney RoellSARASOTA COUNTY, Fla. (SNN) — In honor of Sept. 21 being World Alzheimer’s Day, a group of Sarasota researchers hosted a free bilingual memory screening. Intercoastal Medical Group Neurology and Research Clinic offered their free, confidential memory screening in English and Spanish on Thursday from 8 a.m. to 3 p.m. at Robert L. Taylor […]
A healthy diet may lower dementia risk — even if you start late
By Janet Lee – Washington Post Consumer Reports has no financial relationship with any advertisers on this site. Doing puzzles, playing memory-boosting games, taking classes and reading are activities that we often turn to for help keeping our brains sharp. But research is showing that what you eat, how often you exercise and the type of exercise you do […]
Sarasota researchers plan free, bilingual memory screening on World Alzheimer’s Day
Free, bilingual screening on World Alzheimer’s Day Intercoastal Medical Group Neurology and Research Clinic will hold a free, bilingual?memory?screening event on World Alzheimer’s Day on Sept. 21 from 8 a.m. to 3 p.m. at Robert L. Taylor Community Complex, 1845 John Rivers St., in Sarasota. The goal of the confidential? screening in English and Spanish […]
How the Global Alzheimer’s Platform Foundation Contributed to AAIC
Revolutionary Studies, Record Breaking Collaboration, and Promising News on Biomarker Studies Top the Charts at AAIC Washington D.C., Aug 31, 2023— Researchers and leaders from the Global Alzheimer’s Platform Foundation® (GAP) assembled with the world’s leading Alzheimer’s researchers, patient advocates, and clinicians at the annual Alzheimer’s Association International Conference (AAIC). From the memorable week, […]
Aumentan los casos de Alzheimer en el Valle de Texas
Jessica Cantu from GAP-Net site El Faro Health and Therapeutics was at the Alzheimer’s Association’s International Conference (AAIC) in Amsterdam and spoke about the creation of the site in Starr County, Texas. En el condado Starr, casi uno en cada cuatro adultos de 65 años de edad en adelante fueron diagnosticados con Alzheimer en el […]
Next On Medicare’s To Do List For Alzheimer’s: Coverage Of PET Scans And Genetic Testing
By Cathy Kelly Medicare policymakers have felt that without an effective approved treatment, coverage of amyloid PET scans and APOE4 genetic tests was not warranted. But that is changing. There is more to Medicare coverage for Alzheimer’s treatment than Leqembi, Eisai Co., Ltd. and Biogen, Inc.’s newly-approved amyloid-targeting monoclonal antibody. Now the program also is considering amending restrictive coverage […]
Broader Medicare Coverage For Leqembi Begins As CMS-Backed Registry Opens For Business
By Cathy Kelly There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years. The Centers for Medicare and Medicaid Services is sticking with its plan to provide broader Medicare coverage for Eisai Co., Ltd. and Biogen, Inc.’s Leqembi for Alzheimer’s – now that […]
Global Alzheimer’s Platform Foundation: Full FDA Approval of Leqembi Equals Hope
The FDA’s approval comes following the recommendation of an FDA advisory committee, which voted unanimously for Leqembi’s full approval earlier this month WASHINGTON, DC, July 6, 2023 — Following a decision from the U.S. Food and Drug Administration (FDA) granting full traditional approval to Leqembi, a disease-modifying Alzheimer’s treatment from Eisai, Global Alzheimer’s Platform Foundation® (GAP) […]